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Abstract  48 
Raynaud’s phenomenon (RP) is a symptom complex related to impaired digital perfusion and 49 
can occur as a primary phenomenon or secondary to a wide range of underlying causes. RP 50 
occurs in virtually all patients with systemic sclerosis (SSc) and is often the earliest clinical 51 
manifestation in the natural history of the disease. Careful assessment is required in RP 52 
patients to avoid missing secondary causes of RP, including SSc. Digital ulcers (DUs) are a 53 
painful and disabling visible manifestation of the digital vascular injury. Significant progress 54 
has been made in the definition and assessment of DUs and understanding ulcer 55 
pathogenesis. There are a wide range of available treatments to both prevent and heal DUs; 56 
some of which are also used in RP management. The present review shall consider the 57 
assessment of patients with RP, including ‘red flags’ suggestive of SSc. We shall review the 58 
pathogenesis, definition and classification across the spectrum of SSc-DU disease, alongside 59 
a review on management approaches including drug therapies and surgery for SSc-RP and 60 
ulcers. We also highlight unmet needs and research priorities in SSc-RP and SSc-DUs and 61 
introduce the concept of a unified vascular phenotype in which vascular therapies may 62 
support disease modification strategies. 63 
Introduction 64 
Systemic sclerosis (SSc) is a complex connective tissue disease which is characterised by 65 
autoimmunity, progressive generalised obliterative vasculopathy and widespread aberrant 66 
tissue fibrosis.1,2 Digital vascular disease (vasculopathy) occurs in virtually all patients with 67 
SSc, ranging from symptoms of Raynaud’s phenomenon (RP) (Figure 1) to irreversible 68 
ischaemic tissue injury causing digital ulcers (DUs) (Figure 2) and sometimes gangrene. 69 
Although SSc is a very heterogenous disease, RP is experienced by the majority (>95%) of 70 
patients, and is the most common symptom and clinical sign of the disease.2,3 Whereas, in 71 
primary RP tissue ischaemia is transient/reversible, in secondary RP (in particular SSc-RP) 72 
persistent tissue ischaemia can occur resulting in digital ulceration and/or gangrene. 73 
However, there are only limited to data to suggest an association between the severity of RP 74 
and DUs4, which likely reflects the complexity of vascular (and skin involvement) in SSc. 75 
 76 
The purpose of this review is to highlight 1) when to suspect SSc in the setting of RP, including 77 
how to assess the patient with Raynaud’s to identify ‘red flags’ indicating potential SSc; 2) the 78 
spectrum of RP and DU disease in SSc encompassing relevant pathophysiology, diagnosis and 79 
classification, and management. We will also highlight current unmet needs and research 80 
priorities in RP and DU disease and discuss the concept of a unified vascular phenotype in 81 
which vascular therapy could be a disease modifying strategy. 82 
 83 
Epidemiology 84 
Endothelial injury is an important initiating event in SSc, often manifesting clinically as RP. 85 
Registry analyses suggest ~95% of patients with SSc experience RP.3 The remaining 5% may 86 
not fulfil strict definitions of RP (often necessitating bi-phasic digital colour change) but digital 87 
microangiopathy is usually still evident by the presence of abnormal capillary morphology at 88 
the nailfold. In patients with limited cutaneous SSc, RP may predate the diagnosis of SSc by 89 
many years (sometimes decades).5 Whereas, in patients with diffuse cutaneous SSc, RP 90 
typically develops in closer proximity to the onset of skin sclerosis.5 91 
 92 
DUs are common in patients with SSc and are a major cause of disease-related pain and 93 
morbidity.6 Approximately half of patients with SSc experience DU with a point prevalence of 94 
5 to 10%.7–11 In a study from the European Scleroderma Trials and Research cohort database, 95 
the probability of developing DUs was 70% by the end of the 10-year observation period.12 96 
Several studies have reported that fingertip DUs have a higher prevalence than extensor 97 
ulcers.13–15 In contrast, Ennis et al, reported that extensor ulcers had a similar prevalence (of 98 
6%) and were as similarly disabling as fingertip DUs.11 Patients often develop ulcers affecting 99 
multiple digits simultaneously, including both fingertip and extensor-aspect DUs.15 Despite 100 
the availability of a number of advanced therapies to prevent and treat DUs, around one third 101 
of patients with SSc may develop recurrent ulceration.16  102 
 103 
Clinical presentation 104 
RP is a highly variable symptom complex which results from aberrant digital perfusion. Digital 105 
colour changes (Figure 1) are the cardinal symptom of RP, although other body sites/vascular 106 
beds can be affected including the toes, lips, ears, nose and nipples17 The stereotypical series 107 
of colour changes (physiological basis in parentheses) from attacks of RP consists of initial 108 
white/pallor (vasoconstriction/occlusion of pre-capillary arterioles), then blue/purple 109 
(cyanosis from deoxygenation of sequestered blood), and finally red (post-ischaemic 110 
hyperaemia).17 Digital ischaemia results in significant pain and paraesthesias. In general, the 111 
majority of patients with primary RP will develop symptoms by 30 years of age, whereas, after 112 
40 it is almost always secondary. SSc patients can identify with distinct patterns of RP over 113 
time (that may reflect progression of vasculopathy) with established disease being associated 114 
with  fewer ‘stereotypical’ attacks of RP, and more persistent features of tissue ischaemia.18 115 
Cold exposure is an important trigger for attacks of RP. However, most patients with SSc 116 
experience symptoms throughout the year, given a lower threshold for cold sensitivity in SSc 117 
patients.19 Another important trigger of attacks is emotional stress, both in primary and 118 
secondary RP. A number of classification and diagnostic criteria for RP have been proposed.20–119 
24 In general, these are based on patient reported episodic digital colour changes in response 120 
to cold exposure, most of which have required at least two-colour changes in order to 121 
diagnose or classify RP. 122 
 123 
Approximately, 75% of patients with SSc will develop their first DU episode within 5 years of 124 
their first non-RP symptom7. Moreover, progressive vasculopathy in patients with SSc can 125 
progress to critical ischemia and gangrene, which may necessitate digital amputation, and can 126 
affect approximately 1.5% of patients per year.25 SSc-DUs are associated with significant 127 
pain11,26 with higher analgesia requirements27, reduced health related quality of life28 and 128 
hand-related disability including negative impact on occupation.8,26,29,30 Data from the Digital 129 
Ulcers Outcome (DUO) registry identified that patients with ‘chronic’ and ‘recurrent’ DUs had 130 
greater rates of impairment in activity including occupation, and need for both paid and 131 
unpaid help.16 In addition, these patients also had the greatest need for interventions 132 
including hospitalisation and analgesia.16 The mean annual cost per patient in the European 133 
Union of SSc-DU has been estimated to be €23,619, was higher with complications (€27,309), 134 
and approximately 10% as a result of lost work productivity from patients and/or their care 135 
givers.31 The availability of non-proprietary medications should see this cost fall in the future. 136 
SSc-DUs are typically very slow to heal. In an observational study which included 1,614 digital 137 
lesions, the mean (minimum and maximum) time to healing for ‘pure’ (ischaemic) DUs was 138 
76.2 (7 and 810) days, and for DU derived from calcinosis was 93.6 (30 and 388 days).14 The 139 
DU characteristics associated with a significant delay in ulcer healing included the presence 140 
of fibrin, wet or dry necrosis, eschar, exposure of bone and tendon, and gangrene.  141 
 142 
DU infection can be associated with delayed ulcer healing and osteomyelitis. The most 143 
common (approximately 50%) organism is Staphylococcus aureus.32,33 Enteric organisms 144 
(Escherichia coli and Enterococcus faecalis) have also been reported in around 25% of patients 145 
with SSc-DUs, which highlights the need for patient education about the need for meticulous 146 
wound care.32 Infection has been reported to be associated with greater perfusion (as 147 
assessed by laser speckle contrast imaging) to both the ulcer centre and surrounding area, 148 
and is highly (negatively) correlated with the time to healing.34  149 
 150 
Pathophysiology 151 
Primary RP (‘idiopathic’), is considered an isolated functional vasospastic condition. Whereas, 152 
the aetiopathogenesis of SSc-RP includes (amongst other factors) endothelial cell injury 153 
(possibly autoantibody mediated), an imbalance between vasoconstrictor and vasodilator 154 
factors (e.g. endothelin-1 and nitric oxide, respectively), structural microvascular changes 155 
from progressive microangiopathy, and intravascular factors leading to luminal occlusion and 156 
increased vasoconstriction (e.g. platelet activation and impaired fibrinolysis).2,35 157 
 158 
In general, DUs which occur on the fingertips are considered to be ischaemic (Figure 3). 159 
Whereas, those which occur over the extensor aspects, in particular over the small joints of 160 
the hands, are also related to recurrent trauma at exposed sites, and potentially due to 161 
increased skin tension (Figure 3). Patients can also develop digital ulceration in relation to 162 
underlying subcutaneous calcinosis (Figure 3). The pathogenesis of calcinosis-associated 163 
ulceration may differ significantly (e.g. to ischaemic ulcers) and local mechanical and 164 
inflammatory phenomena may play a significant role.7 Whether SSc-DU can be considered 165 
the consequence of ‘severe Raynaud’s’ is debateable but DU are generally considered a 166 
manifestation of more advanced vasculopathy. Patient-reported RP severity has been noted 167 
to be higher in patients with active DU.4 SSc-associated microangiopathy as assessed by 168 
capillaroscopy (namely capillary drop-out) is strongly associated with a number of clinical 169 
outcomes in SSc including the occurrence of new DU disease.36–39 However, relatively little (if 170 
anything) is known about the pathophysiology of ulcers which occur at other sites of the 171 
hands which are less frequent including at the base of the nail and lateral aspect of the digits. 172 
Irrespective of the underlying cause, skin ulcers can result in significant irreversible tissue loss 173 
(Figure 3). Lower limb macrovascular involvement is well-recognised, in particular in patients 174 
with limited cutaneous SSc and positive anticentromere antibody.40,41 Cutaneous ulceration 175 
of the lower limbs, in general, has not been as comprehensively studied as the fingers with 176 
respect to SSc-DU. The clinical appearances (Figure 4) and aetiopathogenic drivers of lower 177 
limb ulceration (e.g. arterial and venous macrovascular disease, lymphatic abnormalities) can 178 
be diverse and this is an area that warrants further study.42,43  179 
 180 
Assessment 181 
Early recognition of SSc-related RP is important to facilitate earlier diagnosis and 182 
management of SSc disease-related manifestations. Clinicians should be aware of a number 183 
of ‘red flags’ (Box 1) which are strongly suggestive of secondary causes such as SSc. Important 184 
red flags are included in the proposed ‘very early diagnosis of SSc’ [VEDOSS] criteria that 185 
includes RP, puffy fingers and positive antinuclear antibody44 and further validation is 186 
ongoing. The identification of SSc-specific autoantibodies and/or the SSc pattern on nailfold 187 
capillaroscopy strengthens the likelihood of future SSc.44 The second objective of assessment 188 
is to determine the impact of RP including the development of persistent tissue ischaemia 189 
(e.g. DUs). 190 
 191 
Key investigations in the assessment of patients with RP exhibiting any suspicion of secondary 192 
Raynaud’s include the detection of autoantibodies and performing nailfold capillaroscopy, 193 
which are strong independent predictors of progression from isolated RP to SSc.45 In a large 194 
prospective study of 586 RP patients who were followed up over 3,197 patient years, 12.6% 195 
developed definitive SSc.45 Multivariate analysis revealed that predictors of progression to 196 
definitive SSc included positive antinuclear antibody (ANA) (Hazard ratio [HR] 5.67) and SSc-197 
specific autoantibodies (HR 4.7), as well as the SSc pattern on nailfold capillaroscopy (HR 4.5), 198 
and all of which have a high negative predictive value.45  199 
 200 
Clinical investigations 201 
A detailed examination of the hands should be performed including seeking evidence of SSc 202 
skin involvement (e.g. sclerodactyly), signs of persistent digital ischaemia (e.g. digital pitting 203 
scars and ulcers) and other stigmata of SSc (e.g. telangiectasia and calcinosis). The number, 204 
size and distribution of DUs should be assessed including signs of infection (e.g. discharge and 205 
erythema) and deeper progression (e.g. visualisation of underlying tendons and bone). 206 
Asymmetry in RP symptoms and/or DUs may indicate proximal (large) vessel involvement, 207 
which could be amenable to therapeutic intervention. 208 
 209 
Routine investigations also include testing a full blood count, and ESR or CRP.46 Routine 210 
biochemistry (e.g. renal and liver function) and thyroid function can suggest alternative 211 
secondary causes of RP.46 Other investigations are guided by the clinical picture, including 212 
testing of creatine phosphokinase, complements C3 & C4, immunoglobulins with serum 213 
protein electrophoresis, fasting lipid profile (in patients at risk of atherosclerosis), and 214 
performing a chest radiograph to exclude (a bony) cervical rib.46 215 
 216 
As previously described, autoantibodies can help to identify those patients who are at the 217 
greatest risk of developing autoimmune rheumatic diseases, including SSc. Therefore, testing 218 
for autoantibodies should be part of the initial assessment of patients with RP, including those 219 
with symptoms and/or signs of an underlying autoimmune connective tissue disease. The 220 
standard primary method for detecting ANA uses indirect immunofluorescence (IIF) and anti-221 
centromere antibodies are often confirmed by the IIF staining pattern alone. SSc-specific 222 
antigenic targets include anticentromere, anti-Scl-70 (which are commonly available), anti-223 
RNA polymerase (I-III), U3-RNP, Th/To and EIF-2B (which are less frequently available 224 
specialist-/research-antibodies). Scleroderma overlap syndromes can occur with anti-225 
RUVBL1/2, U1-RNP, anti-SS-A/Ro60, anti-Ro52, and anti-Ku and anti-PM/Scl.47 SSc sometimes 226 
occurs in the presence of anti-synthetase antibodies such as anti-Jo-1, anti-PL7 and anti-227 
PL12.48 Commercially available solid phase assays to detect SSc-associated antibodies (e.g. 228 
line blots) can sometimes yield a false positive result and therefore a high index of suspicion 229 
should be maintained, and correlation with IIF staining patterns made where applicable (e.g. 230 
nucleolar staining for anti-U3 ribonucleoprotein and cytoplasmic staining for anti-synthetase 231 
antibodies) and further confirmatory testing requested (e.g. with protein 232 
immunoprecipitation) should be considered in patients with possible SSc.49 233 
 234 
Assessment of digital vascular structure and function 235 
A range of non-invasive methods can be used to assess digital vascular structure and function. 236 
Microvascular alterations are central to the early pathogenesis of SSc and many of the later 237 
disease complications, including DUs. There is also a strong need to assess the macrovascular 238 
system in patients with SSc. Some patients develop a disease-related SSc macroangiopathy, 239 
whereas, others develop macroangiopathy related to atherosclerosis5051 particularly when 240 
classical cardiovascular risk factors coexist. Furthermore, involvement of the ulnar artery has 241 
been reported to be strongly predictive of future  DUs.52,53  242 
 243 
Nailfold capillaroscopy 244 
Nailfold capillaroscopy is a non-invasive imaging technique which allows the microcirculation 245 
to be visualised in situ including examination of capillary morphology and architecture. The 246 
key importance of performing nailfold capillaroscopy is reflected by the inclusion of 247 
capillaroscopy in the 2013 American College of Rheumatology/European League Against 248 
Rheumatism classification criteria for SSc.54 Nailfold capillary abnormalities have also been 249 
reported to be predictive of future DUs and other manifestations of SSc.36–38,55 250 
 251 
Capillaroscopy is performed at the nailfold where the capillaries of the distal row lie parallel 252 
(compared to perpendicular) to the surface of the skin, and therefore allows them to be 253 
visualised in their entirety. Nailfold capillaroscopy can be performed using a wide range of 254 
low- and high-magnification devices. Low-magnification devices56,57 including the 255 
dermatoscope, stereomicroscope and ophthalmoscope allow for a global (wide-field) 256 
assessment of the nailfold area. Assessment at low-magnification allows the user to assess 257 
whether the nailfold capillaries and architecture are broadly normal or abnormal. In the 258 
future, the availability of low-cost, low-magnification USB-microscopes may broaden access 259 
to capillaroscopy. High-magnification (x200-600) videocapillaroscopy is considered the ‘gold 260 
standard’ and allows detailed examination of individual capillaries. Semi-quantitative 261 
assessment (e.g. measurement of capillary diameter and numbers) can also be performed 262 
and has been proposed as a promising future tool/biomarker to assess disease activity, and 263 
possibly as an outcome measure for therapeutic trials of SSc-vasculopathy.58 264 
 265 
Normal nailfold capillaries (Figure 5) have a homogeneous, ‘hair-pin’ like appearance with a 266 
regular distribution. In SSc-spectrum disorders the ‘scleroderma’ capillaroscopic pattern 267 
(Figure 5) includes enlarged (including ‘giant’ capillaries), capillary loss (‘loop dropout’) and 268 
microhaemorrhages. Characteristic microvascular alterations can also be identified in other 269 
connective tissue diseases, in particular, dermatomyositis (Figure 5). Cutolo proposed 270 
classification into the ‘early’, ‘active’ and ‘late’ scleroderma patterns.59 Initially there are a 271 
few giant capillaries and microhaemorrhages (‘early’), which subsequently increase in 272 
number, with moderate loss and mild disorganisation of capillaries (‘active’). Finally, there is 273 
severe loss of capillaries with gross disorganisation of the capillary architecture with extensive 274 
avascular areas and marked evidence of aberrant neovascularization (‘late’ changes). The 275 
recently externally validated ‘fast track’ decision algorithm allows individuals with a range of 276 
prior capillaroscopic experience to successfully differentiate between abnormal (i.e. 277 
scleroderma patterns) from non-scleroderma patterns, with excellent reported reliability.60  278 
 279 
Microvascular structural abnormalities (as assessed by capillaroscopy) have been reported to 280 
be associated with functional microvascular disease (i.e. lower perfusion) in patients with 281 
SSc.61,62 The agreement between objective non-invasive microvascular imaging and patient-282 
reported assessment of digital vascular function is poor and explanations for such findings 283 
have not yet been fully elucidated.63 Future research is indicated including to assess the 284 
potential benefit of combining assessment of microvascular structure and function for use as 285 
a combined outcome measure in future clinical trials of SSc-vasculopathy. 286 
 287 
Laser-based techniques 288 
Laser Doppler imaging (LDI) has been widely used in research to investigate the 289 
pathophysiology of RP and SSc.64,65 LDI and other laser Doppler-based techniques utilise the 290 
Doppler phenomenon, in which the wavelength of light changes from interaction with a 291 
moving object, which can be measured. Unlike laser Doppler flowmetry which measures 292 
perfusion at a single point, LDI measures blood flow over an area to build a global map of 293 
perfusion. LDI has also been used in a number of therapeutic trials to assess treatment 294 
response in a laboratory-based setting.66,67 Laser speckle contrast imaging is an emerging 295 
imaging technique which allows constant measurement of perfusion over a large area, with 296 
higher spatial and temporal resolution than laser Doppler-based techniques.68 Recent 297 
evidence suggests that laser speckle contrast imaging is a highly reliable method to assess 298 
peripheral blood perfusion in patients with SSc and healthy controls.68,69 Laser speckle 299 
flowmetry measures perfusion at a single point and requires further research including to 300 
examine the discriminatory capacity (e.g. between primary and secondary RP) of the 301 
technique.70 302 
 303 
Infrared thermography 304 
Infrared thermography uses a camera to measure skin surface temperature which is an 305 
indirect measure of tissue perfusion (from small and large blood vessels) (Figure 5).71 306 
Thermographic assessment has been reported to enable the successful distinction between 307 
primary and secondary RP.71 Patients with RP (compared to healthy controls) often have 308 
cooler fingertips than the dorsal aspect of the hands. As below, some thermography protocols 309 
include a dynamic assessment including through a ‘cold challenge’ (Figure 5). The use of 310 
infrared thermography has been traditionally limited to specialist centres due to the historical 311 
high-cost of thermographic cameras and use of a temperature-controlled laboratory to 312 
perform provocation tests. However, the availability of relatively low-cost mobile phone-313 
based thermographic imaging devices may facilitate wider access to infrared thermography 314 
used under ambient conditions.69 In addition, there are significant differences in 315 
thermography imaging protocols between centres and internationally agreed 316 
protocols/consensus would help facilitate larger multi-centre studies of SSc-vasculopathy and 317 
potential future incorporation into routine clinical practice.  318 
 319 
Dynamic assessment of microvascular function 320 
A number of previous studies have incorporated some form of local provocation (e.g. local 321 
cold exposure or iontophoresis of vasoactive substances), to distinguish between primary and 322 
secondary RP.6372 A subsequent ‘rewarming’ challenge during thermographic assessment has 323 
also been advocated. For example, Anderson et al73 reported that a ‘distal-dorsal difference’ 324 
of >1°C at 30°C  between the fingertips and the dorsum of the hand differentiated between 325 
primary and secondary RP.   326 
 327 
Doppler ultrasound 328 
Doppler ultrasound is a useful tool which can identify significant macrovascular disease of the 329 
upper and lower limbs.74 Doppler ultrasound is a relatively simple, non-invasive and 330 
reproducible test; however, it does require specialist training to make the necessary 331 
measurements.41,74 The ankle brachial pressure index is an example of Doppler ultrasound 332 
and is calculated by the ratio of the systolic blood pressure in the upper and lower limbs, 333 
which can indicate the presence of significant lower limb ischaemia.74 Abnormal colour and 334 
power Doppler sonography of the hand have been reported to be associated with past and 335 
new DUs in patients with SSc.75,76 336 
 337 
Angiography 338 
Formal angiography is indicated in the presence of confirmed large vessel pathology including 339 
by Doppler ultrasound in order to define the anatomy of the causative vascular lesion/s.77 340 
Imaging techniques include digital subtraction angiography (DSA), computerised tomography 341 
(CT) angiography and magnetic resonance imaging (MRI) angiography. An advantage of CT 342 
and MRI angiography is that intra-arterial access is not required; however, endovascular 343 
procedures can be performed at the time of DSA.77  Furthermore, a disadvantage of both CT 344 
and MRI angiography is poor visualisation of the distal limb vessels.77  345 
 346 
Definition and classification of digital ulcers 347 
This is hugely challenging and there is a key need to accurately define and classify SSc-DUs, 348 
not only for clinical practice to inform therapeutic decision making, but also to develop new 349 
treatments.678 A number of previous studies have reported that the inter-rater reliability of 350 
expert SSc clinicians is poor to moderate at best79–81, In particular, the inter (between) rater 351 
reliability has been very low.79–81 This is a major concern in the design of multi-centre clinical 352 
trials and highlights the need for multiple ulcer assessments to be performed by the same 353 
rater. Furthermore, the agreement between individual patients and clinicians is very low, 354 
irrespective of the addition of ‘real world’ clinical contextual information (e.g. the severity of 355 
associated pain and the presence of discharge).80 Different ulcer definitions have been used 356 
in recent multi-centre clinical trials of drug therapies for SSc-DU disease.82–86 Recent initiatives 357 
to develop DU definitions have been undertaken by the auspices of the World Scleroderma 358 
Foundation (WSF) and the United Kingdom Scleroderma Study Group.81,87 Both sets of 359 
definitions have included a ‘loss of epithelium’ and that if ulcer debridement was likely to 360 
confirm the presence of a DU, then it should be deemed an ulcer.81,87 Although both 361 
definitions had high levels of intra-rater reliability (0.90 and 0.71, respectively), the inter-rater 362 
reliability was significantly higher for the WSF definitions (0.51 and 0.15, respectively)81,87, 363 
although no studies have compared reliability of different methods using the same image 364 
bank.  365 
 366 
In general, the assessment of DUs in clinical practice and research relies upon the distinction 367 
between healed/non healed ulcers and clinician experience-based judgement.88 The Digital 368 
Ulcer Clinical Assessment Score in Systemic Sclerosis (DUCAS) is a proposed clinical score 369 
which includes the number of DUs, new digital ulceration, the presence of gangrene, need for 370 
surgical approach (above standard of care), infection of the DU, unscheduled hospitalisation 371 
for DU, and analgesics needed to control DU pain.88 Early data supports that the DUCAS has 372 
good levels of face, content validity and construct validity, and warrants further investigation 373 
for use in clinical practice.88 In a recent DeSScipher/European Scleroderma Trials and 374 
Research group (EUSTAR) survey which included complete responses from 84 centres, three 375 
items were considered essential for DU evaluation.89 These were the number of DU (which 376 
were defined as loss of tissue), recurrent DU, and the number of new DU.89 Furthermore, 377 
similar to the previously described study from the DUO registry, 80% of the centres also 378 
favoured categorisation of DU into ‘episodic’, ‘recurrent’ and ‘chronic’.89 379 
 380 
Another potential approach to assessment could involve the use of ulcer photographs. A 381 
recent pilot study demonstrated that it was feasible for patients with SSc to ‘monitor’ their 382 
own lesions by taking photographs with a smartphone camera over an extended period of 383 
weeks.90 Furthermore, computer-assisted digital planimetry has been applied to SSc-DUs with 384 
excellent intra- and inter-rater reliability, either by fitting an eclipse to the shape of the ulcer, 385 
or by tracing the ulcer exterior by freehand.91 Whereas, such an approach only measures ulcer 386 
surface dimensions, ultrasound also allows deeper measurement (e.g. of depth). Ultrasound 387 
has been used to assess SSc-skin ulcers, including objective measurement of ulcer 388 
morphology and extent, and could also provide novel insights into pathogenesis.92–94 In a pilot 389 
study which examined high-frequency ultrasound to assess a range of (fingertip, extensor, 390 
and calcinosis-related) DUs, the average width and depth was 6mm and 1mm, respectively, 391 
which highlights the potential challenge of assessing ulcers by means of visual inspection 392 
alone.92  393 
 394 
Management 395 
General approach  396 
Patient education is central to management of SSc-RP and DUs and should be delivered as 397 
part of a dedicated multi-disciplinary team, including specialist rheumatology nursing. Care 398 
should be taken by patients to avoid unnecessary trauma to the digits to prevent potential 399 
tissue ulceration, protection against the cold, and avoiding emotional stress. Patients should 400 
be counselled, and supported in their efforts, about the importance of smoking cessation 401 
because smoking promotes vasoconstriction.95,96 Smoking has been reported to be associated 402 
with more severe digital vascular disease95 including in relation to the intensity of 403 
smoking.95,96 Patients should seek early medical advice about new and/or worsening ulcers, 404 
including potential signs of infection. The development of persistent digital ischaemia should 405 
prompt the patient to seek emergency medical advice. As previously described, DUs can be 406 
infected (Figure 2) and there should be a low threshold for prescribing appropriate antibiotic 407 
therapy. DUs can also be exceptionally painful and therefore sufficient analgesia is required 408 
and often requires the introduction of opioid-based analgesia.  409 
 410 
Differential diagnosis of critical digital ischaemia 411 
Critical digital ischaemia/gangrene (Figure 2) is a medical emergency which requires prompt 412 
assessment and introduction of treatment.97 This can occur as a result of both SSc-related 413 
(e.g. non-inflammatory angiopathy) and non-SSc related causes (e.g. smoking) 98. Thorough 414 
investigation is required because some of these causes are potentially modifiable (e.g. large 415 
vessel disease and embolic disease).  416 
 417 
Non-pharmacological interventions 418 
Patients should be managed by an expert multi-disciplinary team including (but not limited 419 
to) rheumatology specialist nursing, physiotherapy and occupational therapy including 420 
education on lifestyle modification and functional adaptions (e.g. keeping warm and 421 
protecting the fingers to avoid traumatic ulcers).99,100 Furthermore, meticulous wound care is 422 
mandatory for all ulcers to prevent infection and to minimise further tissue damage/loss.101 423 
The ulcer wound bed should be closely examined for signs of inflammation/infection, hyper-424 
proliferation around the wound edges, evidence of exposure of the deeper structures (e.g. 425 
bone and tendon) and hydration status. For example, if the ulcer is ‘wet’ then appropriate 426 
dressings (e.g. with hydrogel and hydrocolloids) should be selected with an aim to reduce 427 
moisture/dry the wound, and vice versa for ‘dry’ wounds (with alginates and 428 
antimicrobials).46 As previously described, clinicians should actively exclude proximal (large) 429 
vessel involvement early in the setting of digital ischaemia including ulcers, as this could 430 
potentially be amenable to therapeutic intervention. Non-surgical DU debridement is being 431 
performed by some clinicians in rheumatology and can be performed physically 432 
(‘mechanical’) with a scalpel or chemically (e.g. by using autolytic dressings). DU debridement 433 
removes non-viable (e.g. necrotic material) and can release pus, both of which can promote 434 
ulcer healing. Appropriate local analgesia is essential for successful DU debridement.102 435 
However, at present there is not strong evidence-base to support debridement in SSc at 436 
present, and requires further research. Furthermore, there is significant geographical 437 
variation in DU debridement. For example, in a survey which included responses from 137 438 
rheumatologists, the majority (80%) of North American and European responders reported 439 
that they never or rarely debrided DUs, compared to 37% of Europeans.103 Work is currently 440 
underway to understand the barriers to DU debridement amongst clinicians in rheumatology. 441 
Other non-pharmacological interventions have been trialled include (but are not limited to) 442 
hyperbaric oxygen in patients with refractory DU disease.104,105 443 
 444 
Pharmacological interventions 445 
There a wide range of treatments to prevent and treat (heal) DUs; some of which are also 446 
used for RP (Figure 6). It is important to be aware how the pharmacological treatment of DU 447 
disease is potentially related to underlying RP. Primary RP usually requires no 448 
pharmacological treatment and is managed by general/lifestyle measures (e.g. cold 449 
avoidance and keeping warm).46 Secondary RP is managed by relatively ‘mild’ oral 450 
vasodilatory drug therapies. Whereas, secondary RP and DU is managed with several different 451 
combinations including specific vasoactive therapies (e.g. bosentan). Drug treatments for DU 452 
disease should be tailored to the individual as there may be significant overlap/treatment 453 
benefit for other vascular-based complications (e.g. pulmonary arterial hypertension). 454 
Although a number of drug therapies have been explored (including but not limited to) 455 
statins, antioxidants, and anti-platelets/anticoagulation106–110, in this review we shall focus on 456 
the most commonly used drug therapies for SSc-DU disease (and RP). 457 
 458 
Vasoactive therapies 459 
Vasoactive therapies attempt to address the underlying factors implicated in the 460 
pathogenesis of SSc-DUs (and SSc-RP). Calcium channel blockers (CCBs) are often used first 461 
line although, although clinicians are increasingly using phosphodiesterase type-5 (PDE5) 462 
inhibitors earlier in the treatment of SSc-associated digital vasculopathy, commonly in 463 
combination with CCBs. Vasodilatory side effects are not uncommon with vasoactive 464 
therapies (e.g. headaches and lower limb oedema) and are more common in patients in 465 
higher doses and potentially drug therapies in combination. Treatment with vasodilator 466 
therapy has been reported to be associated with a reduction in the development of DU.7 In 467 
particular, there is some evidence that treatment with vasodilatory therapies (e.g. CCBs and 468 
PDE5 inhibitors) is associated with approximately 30% reduction in DU development.84,111 469 
There is also some evidence that PDE5 inhibitors can improve the healing of ulcers112; 470 
however, for example no difference was observed in a recent placebo-controlled trial of 471 
sildenafil (discussed later). Despite a strong therapeutic rationale (including vascular 472 
remodelling) for therapies which target the renin angiotensin system (e.g. ACE inhibitors and 473 
angiotensin receptor blockers)113, there is no convincing evidence for SSc-RP or SSc-DU 474 
disease. For example, in a multi-centre, randomised, placebo-controlled trial of quinapril 475 
which included 210 patients with limited cutaneous SSc or autoimmune RP (RP and a SSc-476 
associated autoantibody), after 2 to 3 years of treatment there was no difference in DU 477 
disease, or other vascular complications including RP and pulmonary artery pressure.83 478 
Bosentan, an endothelin-1 receptor antagonist which is licensed in Europe for DU disease, 479 
reduces the number of new DUs, but does not impact DU healing.82,114 In a double-blind, 480 
placebo-controlled trial which included 188 patients with at least one DU, treatment with 481 
Bosentan for 20 weeks was associated with a 30% reduction in new DUs, but not DU healing.82 482 
In contrast, recent clinical trials of Macitentan did not reduce new DUs over 16 weeks85 483 
(possibly owing to differences in study populations, prior intervention and study design).115 484 
Intravenous prostanoids (given over 3 to 5 days) reduce the number of new DUs and fosters 485 
ulcer healing.116–118 Prostanoids are also used in the context of critical digital ischaemia. There 486 
are no studies which have specifically assessed combination vasoactive therapies; however, 487 
the combination of PDE5 inhibition and endothelin receptor blockade has been reported to 488 
be a powerful treatment combination for digital vasculopathy.119,120 489 
 490 
Other treatments 491 
Surgical intervention is indicated for severe RP and DU disease refractory to medical 492 
management.121  Indications for surgery include (but are not limited to) severe pain (which 493 
suggests tissue necrosis), secondarily infected ulcers, and to remove underlying calcinotic 494 
material.121 There is increasing worldwide experience in performing digital (periarterial) 495 
sympathectomy and earlier intervention may be beneficial in patients with severe Raynaud’s 496 
and early digital ischaemia.122–125 There is also increasing interest in botulinum toxin injection, 497 
which promote local arterial vasodilation.126,127 However, at the present time, the evidence 498 
base is limited and further research is needed in this area. For example, in a recent double-499 
blind, placebo-controlled, laboratory-based clinical trial, local injections of botulinum toxin 500 
did not significantly improve blood flow to the hands in patients with SSc-RP.128 Furthermore, 501 
although there were improvements in a number of secondary clinical outcomes (e.g. 502 
Raynaud’s Condition Score), these were of questionable clinical benefit. Autologous fat 503 
grafting and stem cell transplant is a novel treatment approach which has also been shown 504 
to benefit DU healing.129–132 505 
 506 
Unmet needs 507 
There are a number of important unmet clinical needs and research priorities. Better 508 
approaches to the assessment and treatment of RP and DUs are urgently needed. Treatment 509 
of Raynaud’s is seldom fully effective133 and approximately one third of patients with SSc have 510 
refractory DU disease, despite advanced vascular therapies. Treatments for RP and DUs can 511 
be poorly tolerated due to vasoactive side-effects, and well-tolerated, effective treatments 512 
are urgently needed. One approach could be to develop locally-acting vascular approaches to 513 
treatment which would likely be well tolerated from the lack of significant/absence of 514 
systemic vasodilation.  515 
 516 
A major barrier to drug development programs relates to the suitability of existing outcome 517 
measures of efficacy. Significant concerns have been raised about our current methods to 518 
assess treatment efficacy in RP, including the Raynaud’s Condition Score diary .134 A key issue 519 
is that current outcome measures do not fully capture the complex, multi-faceted patient 520 
experience of either RP or DUs 135,136. A recent multinational qualitative research study 521 
identified 7 inter-related themes (and subthemes) of the patient experience of SSc-RP that 522 
comprised  physical symptoms, emotional impact, triggers and exacerbating factors, constant 523 
vigilance and self-management, impact on daily life, uncertainty, and adaptation.137 524 
International collaborative research is ongoing to develop novel patient reported outcome 525 
instruments for both RP and DUs.   526 
 527 
It has been suggested that all DUs could have a potentially treatable ischaemic component 528 
and should all be included in DU clinical trials. .138 Recent clinical trials82,84,114,139 of drug 529 
therapies for SSc-DUs have generally focussed on fingertip DUs, on the premise that such DUs 530 
are primarily driven by tissue ischaemia and more likely to benefit from vascular therapies. 531 
Recent studies have shown that both fingertip and extensor DUs have a relatively (compared 532 
to surrounding non-ulcerated skin) ischaemic core (as assessed by LDI) and with a reduction 533 
in ischaemia with ulcer healing.140,141 In a double-blind, randomised, crossover, placebo-534 
controlled study, the microvessels in the ischaemic DU centre were responsive to topical 535 
glyceryl trinitrate with an increase in perfusion, and with a similar effect observed for both 536 
fingertip and extensor DUs.142 In addition, microangiopathic SSc-type capillary abnormalities 537 
(e.g. enlargement and neoangiogenesis) have been reported immediately adjacent to the skin 538 
surrounding both fingertip and extensor DUs, which could suggest that microangiopathy 539 
contributes to the pathogenesis of both.143 Macrovascular involvement also likely reduces 540 
hand perfusion globally and could also promote the development of all types of SSc-DUs.53 541 
 542 
Three major challenges complicating the design of RP clinical trials (and practice) are 1) the 543 
impact of the weather; 2) the lack of a robust ‘target’ akin to a ‘treat to target’ approach in 544 
inflammatory arthritis; and 3) the heterogeneity in the natural history of DU healing. In a 545 
recent randomised, placebo-controlled study, the time to DU healing which was the primary 546 
end point of the study (hazard ratio of 1.33 and 1.27, respectively) was not reached. The 547 
authors speculated that this could potentially be due to the unexpected high healing rate in 548 
the placebo group.84 Furthermore, the contrasting findings of the within-class clinical trials of 549 
Bosentan and Macitentan115, and recent trials of promising treatments such as Selexipag (a 550 
non-prostanoid prostacyclin receptor agonist)144 were disappointing.  551 
 552 
Generalised vascular disease is a cardinal feature of SSc and likely to be responsible for the 553 
development of many of the organ-based complications associated with the disease. 554 
Biomarker studies support the presence of systemic vasculopathy, and autopsy studies have 555 
revealed silent lung and kidney vascular involvement.145 For example, similar nailfold and 556 
pulmonary abnormalities, as well as progression of interstitial lung disease, have been 557 
reported in SSc.146,147 DUs have also been reported to be associated with a worse disease 558 
course and prognosis including in patients with early disease.148 In a study from the EUSTAR 559 
database, the use of CCBs was associated with a significant decrease in the prevalence (odds 560 
ratio of 0.41) of left ventricular ejection fraction <55%.149 Therefore, confirmation of a unified 561 
(generalised) vascular phenotype in SSc could herald the use of vascular acting therapies as 562 
disease-modifying agents, in particular in patients with early SSc before the onset of 563 
significant skin fibrosis and organ dysfunction. A necessity to such an approach would be the 564 
successful case identification of patients with the earliest forms of SSc, likely using RP as the 565 
key entry symptom. Patients, including those with RP, are increasingly using mobile health 566 
technology to monitor their symptoms, and this can be a powerful method to encourage 567 
timely engagement with health care professionals.150,151 568 
 569 
Conclusions 570 
In conclusion, RP is a cardinal feature of SSc and is usually the first manifestation of the 571 
disease, thereby potentially allowing early diagnosis of SSc. Key investigations include the 572 
detection of autoantibodies and performing capillaroscopy. Structural and vascular imaging 573 
plays a major role in both the diagnosis of disease and managing the peripheral vascular 574 
disease complications. DUs are a visible ischaemic manifestation of the SSc-disease process 575 
and represents secondary Raynaud’s with digital vascular compromise. Digital ischaemia 576 
resulting in DUs and gangrene are serious complications which require prompt assessment 577 
and initiation of treatment. Patients should be managed by an expert multi-disciplinary team 578 
and first line treatment is non-pharmacological interventions including patient education. 579 
Although there are a range of vasodilator treatments to both prevent and treat DUs/RP, a 580 
number of patients experience refractory digital vascular disease. There are a number of 581 
unmet clinical and research needs relating to RP and DUs including establishing treatment 582 
efficacy in clinical trials. However, good progress is being made through international 583 
collaborative research. The concept of a unified vascular phenotype coupled with the early 584 
diagnosis of SSc, could potentially allow a paradigm shift in which vascular-acting therapies 585 
could be judiciously deployed as a means of disease-modification. 586 
 587 
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 1001 
 1002 
Figure 1: Raynaud’s phenomenon. Mobile phone photographs taken of attacks of Raynaud’s 1003 
in a patient with primary Raynaud’s phenomenon and established peripheral nerve damage 1004 
from entrapment neuropathies. There is pallor (index, middle and little fingers) and cyanosis 1005 
(ring finger) with sparing of the thumb which is suggestive of primary Raynaud’s 1006 
phenomenon.152 1007 
 1008 
Figure 2: Digital ulcers and complications in systemic sclerosis. Ischaemic digital ulcers on 1009 
the fingertip (A) and volar aspect (B) of the digits. Digital ulcers on the extensor aspect (C) of 1010 
the hands overlying the small joints and calcinosis-related (D) digital ulceration. Infected 1011 
digital ulcer (E) and critical digital ischaemia (F). 1012 
 1013 
Figure 3: The pathogenesis of systemic sclerosis-related digital ulcers. Proposed schematic 1014 
illustrating how the major factors could be potentially involved in both ulcer development 1015 
and healing. Focal ischaemia or trauma promotes loss of tissue integrity and ulceration. As 1016 
the digital ulcer develops the central core of tissue ischaemia progresses. There is often 1017 
inflammation/erythema of the surrounding the non-ulcerated skin and the 1018 
mechanism/implications of this is currently unknown. It could be postulated that this 1019 
represents increased blood flow from neoangiogenesis and promotes ulcer healing. However, 1020 
excessive blood flow could also result in a form of reperfusion injury and exacerbate further 1021 
tissue injury. In addition, Infection is also associated with peri-ulcer inflammation. Over time 1022 
with ulcer healing the tissue is either restored to normal or there is evidence of persistent 1023 
digital ischaemic tissue loss. Digital pitting scars can also occur without prior ulceration. 1024 
 1025 
Figure 4: The heterogeneity of lower limb cutaneous ulcer disease in SSc. A-D: significant 1026 
variation in appearance in ulcer appearance reflecting differences in aetiopathogenesis 1027 
including macrovascular arterial/venous involvement and other drivers (e.g. lymphatic 1028 
abnormalities). E&F: Evolution of lower limb refractory ischaemia/ulceration in a patient with 1029 
dcSSc (anti-Scl-70 antibody). E: cyanosis and small subungal ischaemic digital ulcer (2017). F: 1030 
ischaemic paronychial ulceration right great toe despite combination therapy with sildenafil, 1031 
bosentan and angiotensin II antagonist (2018). 1032 
 1033 
Figure 5: The utility of non-invasive digital microvascular structural and functional imaging 1034 
in the assessment of CTD-related digital vasculopathy. A, Low-powered (50x) magnification 1035 
of the nailfold in primary Raynaud’s; B, High-magnification (x200) of the same nailfold in A 1036 
revealed normal-appearance uniformly spaced and sized hairpin capillary loops; C, Low-1037 
magnification appearance of nailfold in limited cutaneous systemic sclerosis with visible giant 1038 
capillaries; D, Corresponding high-magnification image of the same nailfold in C revealing 1039 
giant capillaries and capillary drop-out; E & F, Low and high-magnification nailfold 1040 
capillaroscopic images in dermatomyositis revealing characteristic ramified (‘bushy’) 1041 
capillaries; G, Thermal image of the hands of a patient with eosinophilic fasciitis 5 minutes 1042 
following local cold challenge revealing a healthy-looking  preserved positive longitudinal 1043 
gradient in the early stages of re-warming not consistent with Raynaud’s phenomenon; H, 1044 
Thermal image of the hands 5 minutes following local cold challenge in Raynaud’s 1045 
phenomenon with a negative longitudinal gradient consistent with delayed re-perfusion 1046 
 1047 
Figure 6: Treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis. 1048 
Adapted from the Consensus best practice pathway of the UK Scleroderma Study Group: 1049 
digital vasculopathy in systemic sclerosis.46 A number of drug therapies are used for the 1050 
treatment of both RP and digital ulcers in SSc. The potential benefits vs. the risks of adjunctive 1051 
therapies must be considered on an individual patient basis. For example, anti-platelet 1052 
therapies and anticoagulation may be potentially hazardous in patients with SSc due to 1053 
potential gastrointestinal bleeding from gastric antral vascular ectasia, and statins can have 1054 
adverse muscle effects in patients with SSc-myopathy. 1055 
 1056 
Box 1: Red flags in the setting of Raynaud’s phenomenon which suggest the presence of 1057 
systemic sclerosis. 1058 
Cutaneous  Puffy fingers* 
Sclerodactyly and/or proximal skin thickening 
Digital ulcers  
Digital pitting scars 
Telangiectasia 
Gastrointestinal  Gastro-oesophageal reflux disease* 
Abnormal oesophageal manometry  
Imaging evidence of gastrointestinal motility 
abnormalities 
Immunological Positive antinuclear antibody* 
SSc-specific autoantibodies 
Vascular Abnormal capillary morphology  
 1059 
*These suggest the ‘very early diagnosis of systemic sclerosis’ and is confirmed by either the 1060 
presence of systemic sclerosis-specific autoantibodies and/or the scleroderma pattern on 1061 
nailfold capillaroscopy.44  1062 
 1063 
Key points 1064 
• Vascular injury and Raynaud’s phenomenon are the earliest manifestations of 1065 
systemic sclerosis. 1066 
• Patients with Raynaud’s phenomenon need careful assessment to identify secondary 1067 
causes including systemic sclerosis and key investigations include performing 1068 
capillaroscopy and the detection of autoantibodies.  1069 
• Raynaud’s and ischaemic complications including digital ulcers are a major cause of 1070 
disease-related morbidity in systemic sclerosis.  1071 
• The definition and assessment of digital ulcers can be very challenging and recent 1072 
efforts have made progress in this field. 1073 
• There are a number of available treatments to both prevent and heal digital ulcers. 1074 
• The concept of a unified vascular diagnosis could herald the onset of a potential 1075 
disease-modifying effect for vascular acting therapies in systemic sclerosis. 1076 
 1077 
